Day 1 – 21 September 2021

09:00–09:25 Welcome Word
09:25–09:30 Break

Interactive Poster session 1
Moderators: Jürgen Floege (Germany) & Hong Zhang (China)

Long-Term Value of the International IgAN Prediction Tool and the Role of Hematuria
Robin Ebbestad (Sweden)

Transforming MEST-score to prognostic staging in IgA-nephropathy
Yngvar Haaskjold (Norway)

An increasing incidence of IgA nephropathy and Henoch-Schönlein purpura during the 23 years of biopsy survey in the Czech Republic
Dita Maixnerova (Czech Republic)

A key role for soluble CD89 as inducer of mesangial proliferation in childhood IgA nephropathy
Alexandra Cambier (France)

Unravelling the complexity of pathogenic immune complexes in IgA nephropathy
Katrin Scionti (United Kingdom)

Probing IgA1 using selective digestion with the IgA1 protease from Streptococcus oralis to identify the pathogenic form of IgA1 in IgAN
Katrin Scionti (United Kingdom)

10:15–10:30 Coffee Break
10:30–11:30 Industry Symposium 2
11:30–11:35 Break

Plenary Session 1
Genetic and epigenetic insights in IgAN
Chair: Ali Gharavi (United States)

Human genetics of IgA system and IgA nephropathy
Krzysztof Kiryluk (United States)

RNA interference in IgAN
Jonathan Barratt (United Kingdom)

Is there a link between collagen IV mutations and IgAN?
Alexandra Cambier (France)

12:25–12:50 Lunch Break

Free Communications 1
Chairs: Vladimír Tesař (Czech Republic) & Rosanna Coppo (Italy)

Impact of VIS649, an APRIL-Neutralizing IgG2 Monoclonal Antibody, on Tetanus- and Diphtheria-Toxoid Vaccination-Elicited Immune Responses in Healthy Volunteers: Phase 1, Randomized, Double-Blind, Placebo-Controlled Study
Jonathan Barratt (United Kingdom)

Low serum immunoglobulin G4 levels and its potential mechanism in IgA nephropathy
Xinyu Tian (China)

Molecular Phenotyping of aberrant IgA1 O-glycosylation in serum of patients with IgA nephropathy
Alyssa Hansen (United States)

Human Mesangial Cell Activation Induced by Endothelin-1 or IgA Nephropathy Patient-Derived Immune Complexes is Blocked by Selective ETA Antagonist Atrasentan
Andrew King (Canada)

A novel ELISA method to measure levels of IgA1-specific IgG antibodies
Katrin Scionti (United Kingdom)

13:50–13:55 Break
13:55–14:55 Panel Discussion 1
Expert Panel: Living with IgAN and understanding what we can learn from the patient journey
14:55–15:00 Break
15:00–15:30 Industry Symposium 6a
15:30–15:35 Break

Plenary Session 2
What role does complement activation play in IgAN?
Chair: Jonathan Barratt (United Kingdom)

Complement in IgAN what we know and what we don't
Richard Lafayette (United States)

A role for the lectin pathway?
Hong Zhang (China)

The alternative pathway of complement activation in IgA nephropathy
Nicholas Medjeral-Thomas (United Kingdom)

16:25–16:30 Break

Plenary Session 3
Where do we go next with the kidney biopsy in IgAN?
Chair: Nicholas Medjeral-Thomas (United Kingdom)

What next for the Oxford Classification?
Ian Roberts (United Kingdom)

The use of Artificial Intelligence in kidney biopsy evaluation
Peter Boor (Germany)

Single cell genomics and spatial transcriptomic technologies to understand kidney disease
Rafael Kramann (Germany)

17:20–17:25 Break

Plenary Session 4
B cells & IgA
Chair: Yusuke Suzuki (Japan)

Fantastic IgA Plasma Cells and where to find them
Jennifer Gommerman (Canada)

25 years since IgA1 glycosylation changes were first described-what will the next 25 years bring?
Jan Novak (United States)

Is IgAN a disease of mistrafficking B cells?
Loreto Gesualdo (Italy)

18:10–18:15 Break
18:15–19:15 Industry Symposium 2
19:15–19:20 Break
19:20–20:20 Industry Symposium 1
20:20–20:25 Break

Interactive Poster session 2
Moderators: Louise Oni (United Kingdom) & Richard Lafayette (United States)

Integrin α1β1 is involved in mesangial-cell activation by IgA1-containing immune complexes from patients with IgA nephropathy
Zhi Qiang Huang (United States)

Differential pathway activation in Ig-producing cells from IgAN patients and healthy controls mediated by cytokine stimulation
Colin Reily (United States)

Characterization of different molecular forms of aberrantly glycosylated IgA1 in the circulation of patients with IgA nephropathy
Stacy Hall (United States)

A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA Nephropathy
Jonathan Barratt (United Kingdom)

Clinical Pharmacology and Population Pharmacokinetic/Pharmacodynamic Modeling of Lectin Pathway Inhibition by Narsoplimab (OMS721)
William Pullman (United States)

Quantitative Analysis of IgA1 O-glycoforms in Familial IgA Nephropathy
Ellenore Craine (United States)


 All times in the symposium programme are in Central European Summer Time – CEST (UTC + 2).




Symposium Secretariat

GUARANT International spol. s r.o.
Českomoravská 19
190 00 Prague 9
Czech Republic

+420 284 001 444